NG
PTGX icon

Norden Group’s Protagonist Therapeutics PTGX Stock Holding History

Norden Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
2,868
+58
+2% +$6.06K 0.03% 479
2026
Q1 		$296K Buy
+2,810
New +$249K 0.03% 470

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norden Group's PTGX Position: Q2 2026 in Review

Norden Group increased its Protagonist Therapeutics (PTGX) stake by 2.1% in Q2 2026, buying an estimated $6.06K and bringing the position to 2,868 shares worth $352K. The position accounts for 0.03% of the portfolio, ranked #479.

Norden Group first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Norden Group held 2,868 shares of Protagonist Therapeutics worth $352K as of Q2 2026.
  • Norden Group bought 58 Protagonist Therapeutics shares in Q2 2026, an estimated $6.06K.
  • Protagonist Therapeutics made up 0.03% of Norden Group's portfolio in Q2 2026, its #479 holding.
  • Norden Group first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.